Literature DB >> 11867170

Mucosal and systemic isotype-specific antibody responses and protection in conventional pigs exposed to virulent or attenuated porcine epidemic diarrhoea virus.

M L de Arriba1, A Carvajal, J Pozo, P Rubio.   

Abstract

Eleven-day-old conventionally reared piglets were inoculated orally with two different doses of the cell-culture adapted strain CV-777 of the porcine epidemic diarrhoea virus (PEDV) or the virulent isolate of the same strain and challenged with the same virulent PEDV 3 weeks later. Pigs inoculated with the two doses of the attenuated virus did not show any typical sign of the disease, and virus shedding was not frequent. In contrast, 31% of pigs exposed to the virulent PEDV developed diarrhoea and virus shedding was demonstrated in 100%. At different postinoculation day (PID) and postchallenge day (PCD) virus-specific antibody-secreting cells (ASC) in gut associated lymphoid tissues (duodenum and ileum lamina propria and mesenteric lymph nodes) and systemic locations (blood and spleen) were assessed by enzyme-linked immunospot (ELISPOT). Only a small response was detected in the groups inoculated with attenuated PEDV, whereas in the group previously exposed to the virulent virus on PID 21 a large number of IgG and IgA ASC was detected. Isotype-specific antibody responses in serum were investigated by ELISA. IgG responses were detected in all groups, although the highest response corresponded to the group inoculated with virulent virus and only this group showed an IgA response. The pigs exposed to virulent PEDV were completely protected against the challenge with a higher dose of the same virulent virus on PID 21 and none of them shed the virus. The pigs inoculated with the attenuated strain were partially protected against the challenge, and 25% of the low dose- and 50% of the high dose-exposed pigs did not shed virus after challenge. All the pigs from a control group, not previously exposed to the virus, excreted the virus in faeces. A strong positive correlation was established between protection and the ASC responses detected in gut associated lymphoid tissues and blood at the challenge day and also between protection and serum isotype-specific antibody titers on that day. In addition, the IgA and IgG ASC responses detected in the blood on PID 21 also correlated with the responses found in the gut associated lymphoid tissues. The ASC and serum antibody responses after the challenge corresponded to a secondary immune response in the groups inoculated with attenuated virus, whereas a primary response was evident in the control group. No increase was seen in any of the parameters studied in the pigs inoculated with virulent PEDV.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11867170     DOI: 10.1016/s0165-2427(01)00417-2

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  37 in total

Review 1.  SARS coronavirus: a new challenge for prevention and therapy.

Authors:  Kathryn V Holmes
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

Review 2.  Porcine epidemic diarrhea: a review of current epidemiology and available vaccines.

Authors:  Daesub Song; Hyoungjoon Moon; Bokyu Kang
Journal:  Clin Exp Vaccine Res       Date:  2015-07-29

3.  An inactivated vaccine made from a U.S. field isolate of porcine epidemic disease virus is immunogenic in pigs as demonstrated by a dose-titration.

Authors:  Emily A Collin; Srivishnupriya Anbalagan; Faten Okda; Ron Batman; Eric Nelson; Ben M Hause
Journal:  BMC Vet Res       Date:  2015-03-15       Impact factor: 2.741

4.  Evaluation of porcine epidemic diarrhea virus transmission and the immune response in growing pigs.

Authors:  Kimberly Crawford; Kelly Lager; Laura Miller; Tanja Opriessnig; Priscilla Gerber; Richard Hesse
Journal:  Vet Res       Date:  2015-05-06       Impact factor: 3.683

5.  Increased frequency of porcine epidemic diarrhea virus shedding and lesions in suckling pigs compared to nursery pigs and protective immunity in nursery pigs after homologous re-challenge.

Authors:  Priscilla F Gerber; Chao-Ting Xiao; Kelly Lager; Kimberly Crawford; Vikas Kulshreshtha; Dianjun Cao; Xiang-Jin Meng; Tanja Opriessnig
Journal:  Vet Res       Date:  2016-11-21       Impact factor: 3.683

6.  Evaluation and Comparison of the Pathogenicity and Host Immune Responses Induced by a G2b Taiwan Porcine Epidemic Diarrhea Virus (Strain Pintung 52) and Its Highly Cell-Culture Passaged Strain in Conventional 5-Week-Old Pigs.

Authors:  Yen-Chen Chang; Chi-Fei Kao; Chia-Yu Chang; Chian-Ren Jeng; Pei-Shiue Tsai; Victor Fei Pang; Hue-Ying Chiou; Ju-Yi Peng; Ivan-Chen Cheng; Hui-Wen Chang
Journal:  Viruses       Date:  2017-05-19       Impact factor: 5.048

7.  Using heterogeneity in the population structure of U.S. swine farms to compare transmission models for porcine epidemic diarrhoea.

Authors:  Eamon B O'Dea; Harry Snelson; Shweta Bansal
Journal:  Sci Rep       Date:  2016-03-07       Impact factor: 4.379

8.  Detection of immunoglobulin (Ig) A antibodies against porcine epidemic diarrhea virus (PEDV) in fecal and serum samples.

Authors:  Priscilla F Gerber; Tanja Opriessnig
Journal:  MethodsX       Date:  2015-10-13

9.  Evaluation of humoral immune status in porcine epidemic diarrhea virus (PEDV) infected sows under field conditions.

Authors:  Kang Ouyang; Duan-Liang Shyu; Santosh Dhakal; Jagadish Hiremath; Basavaraj Binjawadagi; Yashavanth S Lakshmanappa; Rui Guo; Russell Ransburgh; Kathryn M Bondra; Phillip Gauger; Jianqiang Zhang; Terry Specht; Aaron Gilbertie; William Minton; Ying Fang; Gourapura J Renukaradhya
Journal:  Vet Res       Date:  2015-12-14       Impact factor: 3.683

10.  Evaluation of the efficacy of a commercial inactivated genogroup 2b-based porcine epidemic diarrhea virus (PEDV) vaccine and experimental live genogroup 1b exposure against 2b challenge.

Authors:  Tanja Opriessnig; Priscilla F Gerber; Huigang Shen; Alessandra Marnie M G de Castro; Jianqiang Zhang; Qi Chen; Patrick Halbur
Journal:  Vet Res       Date:  2017-10-26       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.